241 related articles for article (PubMed ID: 27770508)
21. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
22. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary invasive mucinous adenocarcinoma.
Chang WC; Zhang YZ; Nicholson AG
Histopathology; 2024 Jan; 84(1):18-31. PubMed ID: 37867404
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods.
Kao HL; Yeh YC; Lin CH; Hsu WF; Hsieh WY; Ho HL; Chou TY
Lung Cancer; 2016 Nov; 101():40-47. PubMed ID: 27794407
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
27. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.
Jang JS; Lee A; Li J; Liyanage H; Yang Y; Guo L; Asmann YW; Li PW; Erickson-Johnson M; Sakai Y; Sun Z; Jeon HS; Hwang H; Bungum AO; Edell ES; Simon VA; Kopp KJ; Eckloff B; Oliveira AM; Wieben E; Aubry MC; Yi E; Wigle D; Diasio RB; Yang P; Jen J
Sci Rep; 2015 May; 5():9755. PubMed ID: 25985019
[TBL] [Abstract][Full Text] [Related]
28. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
30. Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma.
Kishikawa S; Hayashi T; Saito T; Takamochi K; Kohsaka S; Sano K; Sasahara N; Sasa K; Kurihara T; Hara K; Suehara Y; Takahashi F; Suzuki K; Yao T
Mod Pathol; 2021 Apr; 34(4):786-797. PubMed ID: 33024306
[TBL] [Abstract][Full Text] [Related]
31. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
32. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
33. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
34. A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.
Chen K; Li W; Xi X; Zhong J
Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
[TBL] [Abstract][Full Text] [Related]
35. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and genetic analyses of pulmonary enteric adenocarcinoma.
Okada F; Takeda M; Fujii T; Uchiyama T; Sasaki S; Matsuoka M; Nitta Y; Terada C; Maebo K; Morita K; Ishida E; Sawabata N; Ohbayashi C
J Clin Pathol; 2024 Jan; 77(2):111-115. PubMed ID: 36456172
[TBL] [Abstract][Full Text] [Related]
37. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
[TBL] [Abstract][Full Text] [Related]
38. Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements.
Zhang X; Li L; Gao F; Liu B; Li J; Ren S; Peng S; Qiu W; Pu X; Ye Q
Diagn Pathol; 2024 Jan; 19(1):1. PubMed ID: 38173003
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic Features and Response to Therapy of
Drilon A; Duruisseaux M; Han JY; Ito M; Falcon C; Yang SR; Murciano-Goroff YR; Chen H; Okada M; Molina MA; Wislez M; Brun P; Dupont C; Branden E; Rossi G; Schrock A; Ali S; Gounant V; Magne F; Blum TG; Schram AM; Monnet I; Shih JY; Sabari J; Pérol M; Zhu VW; Nagasaka M; Doebele R; Camidge DR; Arcila M; Ou SI; Moro-Sibilot D; Rosell R; Muscarella LA; Liu SV; Cadranel J
J Clin Oncol; 2021 Sep; 39(25):2791-2802. PubMed ID: 34077268
[TBL] [Abstract][Full Text] [Related]
40. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
